Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study

Alex I. Malinin(Johns Hopkins University), Alex Pokov(Johns Hopkins University), Malcolm Spergling, Anthony DeFranco(McLaren Regional Medical Center), Kenneth A. Schwartz(University of California San Diego Medical Center), Dianne E. Schwartz(University of California San Diego Medical Center), Ehtisham Mahmud(University of California San Diego Medical Center), Dan Atar(University of Oslo), Victor L. Serebruany(Johns Hopkins University)

Thrombosis Research

March 25, 2006

10.1016/j.thromres.2006.01.019

Cited by 225

Abstract

Related Papers

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Antiplatelet Trialists Collaboration|BMJ|2002|7k

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

|The Lancet|1996|6.5k

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators|New England Journal of Medicine|2001|6.5k

Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention

Steven R. Steinhubl, Peter B. Berger, J. Tift Mann et al.|JAMA|2002|3.1k

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Shamir R. Mehta, Salim Yusuf, Ron J.G. Peters|ACC Current Journal Review|2002|2.6k